GLUE
No price yet
Announcements
Nothing here yet
Daily updates
- Monte Rosa reported favorable Phase 1 GFORCE-1 results for MRT-8102, showing 80%–90% NEK7 degradation and broad reductions in ASCVD inflammatory and thrombogenic biomarkers, including hsCRP, IL-6, calprotectin, SAA, fibrinogen, and Lp(a). No serious adverse events were reported, and treatment-emergent adverse-event rates were comparable with placebo. Phase 2 studies are planned in coronary artery disease, gout, and hidradenitis suppurativa.Oct 4, 2026
- Monte Rosa reported positive Phase 1 GFORCE-1 results for MRT-8102, showing 80%–90% NEK7 degradation and broad reductions in inflammatory, thrombogenic, and lipid biomarkers, with no serious adverse events. Phase 2 trials are planned for gout in Q4 2026/Q1 2027, coronary artery disease in 1H 2027, and hidradenitis suppurativa in 1H 2027.Oct 1, 2026
FDA designations
Nothing here yet
News
- Monte Rosa Therapeutics reports positive Phase 1 GFORCE-1 results for MRT-8102, showing normalization of key pathogenic drivers of ASCVD in subjects at elevated cardiovascular riskOct 1, 2026
- Monte Rosa Therapeutics will present results from the MRT-8102 GFORCE-1 Phase 1 study in participants at elevated cardiovascular disease riskSep 30, 2026
- Monte Rosa Therapeutics dosed the first patient in the Phase 2 MODeFIRe-1 study of MRT-2359 combined with apalutamide in AR mutation-positive metastatic castration-resistant prostate cancerAug 24, 2026
- Monte Rosa Therapeutics announced positive Phase 1 data for MRT-8102 showing CRP reductionsJan 7, 2026
- Monte Rosa reports compelling MRT-2359 activity with enzalutamide in pretreated metastatic prostate cancerDec 16, 2025